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http://www.globalizationandhealth.com/content/9/1/62RESEARCH Open AccessEpidemiology, management, complications and
costs associated with type 2 diabetes in Brazil: a
comprehensive literature review
Andréa D Bertoldi1*, Panos Kanavos2,3, Giovanny V A França1,4, André Carraro5, Cesar Augusto Ovieda Tejada5,
Pedro C Hallal1, Alessandra Ferrario2,3 and Maria Inês Schmidt6Abstract
Background: With an estimated 74% of all deaths attributable to non-communicable diseases (NCDs) in 2010,
NCDs have become a major health priority in Brazil. The objective of the study was to conduct a comprehensive
literature review on diabetes in Brazil; specifically: the epidemiology of type 2 diabetes, the availability of national
and regional sources of data (particularly in terms of direct and indirect costs) and health policies for the
management of diabetes and its complications.
Methods: A literature search was conducted using PubMed to identify articles containing information on diabetes
in Brazil. Official documents from the Brazilian government and the World Health Organization, as well as other
grey literature and official government websites were also reviewed.
Results: From 2006 to 2010, an approximate 20% increase in the prevalence of self-reported diabetes was observed.
In 2010, it was estimated that 6.3% of Brazilians aged 18 years or over had diabetes. Diabetes was estimated to be
responsible for 278,778 years of potential life lost for every 100,000 people. In 2013, it is estimated that about 7%
of patients with diabetes has had one or more of the following complications: diabetic foot ulcers, amputation,
kidney disease, and fundus changes. The estimated annual direct cost of diabetes was USD $3.952 billion in 2000;
the estimated annual indirect cost was USD $18.6 billion. The two main sources of data on diabetes are the
information systems of the Ministry of Health and surveys. In the last few years, the Brazilian Ministry of Health has
invested considerably in improving surveillance systems for NCDs as well as implementing specific programmes
to improve diagnosis and access to treatment.
Conclusions: Brazil has the capacity to address and respond to NCDs due to the leadership of the Ministry of
Health in NCD prevention activities, including an integrated programme currently in place for diabetes.
Strengthening the surveillance of NCDs is a national priority along with recognising the urgent need to invest in
improving the coverage and quality of mortality data. It is also essential to conduct regular surveys of risk factors
on a national scale in order to design effective preventive strategies.
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Brazil is an upper middle-income country with a popula-
tion of 190,755,799 inhabitants [1] and a per capita gross
domestic product of USD $ 10,993 (current exchange
rate) in 2011. With a land area covering 47% of Latin
America [2], Brazil has marked regional inequalities in
terms of climate, social development, income and other
indicators.
Following democratisation of the country from 1994
onwards, Brazil has experienced a period of economic
growth, which allowed the implementation of social de-
velopment policies [3]. This has led to slow but stable
improvements in social indicators, particularly reduc-
tions in poverty and in regional inequalities. In the 70s
and early 80s, Brazil underwent a period of social mobil-
isation in which people campaigned for basic rights,
including universal health care access. The demand for
greater decentralisation of public resources led to an in-
crease in the budget of cities and states. These factors
contributed to the implementation of the Brazilian Uni-
fied Health System (SUS - Sistema Único de Saúde) in
1990 [4].
SUS is intended to provide healthcare free of charge to
the whole Brazilian population, financed through direct
and indirect sources such as tax revenues, social
contributions, out-of-pocket spending, and employers’
health-care spending [5]. It includes primary health care
units, hospitals, emergency departments, laboratories
and blood centres. In 2006, SUS budget reached around
USD $15 billion, which represents 54% of the country’s
total health expenses [6]. Although access has expanded
over the years, the increasing demands on SUS have had
negative repercussions on the quality of the services
delivered and on waiting times in hospitals and emer-
gency departments [5].
In 2011, 22% of total health expenditure was spent on
the payment of private health insurance [7]. The propor-
tion of out-of-pocket expenses has continued to rise in
spite of the implementation of SUS, from 9% in 1981 to
15% in 2003 and 19% in 2008 [5]. Out-of-pocket ex-
penses are particularly concerning due to the difficulty
in accurately predicting these costs [8] which can lead to
catastrophic health spending. This is a problem affecting
up to 16% of all Brazilian families [8-11].
Brazil and various other Latin American countries
have undergone rapid demographic, epidemiological and
nutritional transitions [12]. Dietary shifts towards low
consumption of fiber and heavy consumption of satu-
rated fatty acids and sugar and sedentary lifestyles
are key contributors to the incidence of obesity, type
2 diabetes, and other chronic diseases [13]. Non-
communicable diseases (NCDs) have become a major
health priority in Brazil with an estimated 74% of all
deaths attributable to NCDs in 2010 [14]. Nationalestimates indicate that people with diabetes experience a
57% greater risk of death than the general population
[15]. Beyond the health burden, diabetes is also respon-
sible for increased use of health services and increased
costs. Between 1999–2001, it was estimated that about
7.4% of all non-pregnancy related admissions to hospi-
tals and 9.3% of all hospital costs in Brazil were attribut-
able to diabetes [16].
In the present study we aimed to: (i) identify existing
data sources on the prevalence of diabetes and its
complications, as well as the direct and indirect costs of
diabetes in Brazil; (ii) describe the prevalence of diabetes
and its complications - retinopathy, nephropathy, neur-
opathy, diabetic foot ulcers, amputation, kidney disease,
fundus changes, vascular complications; (iii) report
evidence on direct and indirect costs; and (iv) review
health policies for the management of diabetes and its
complications.
Methodology
A comprehensive literature search was conducted to iden-
tify articles containing information on type 2 diabetes in
Brazil. The following PubMed search strategy was used:
("diabetes mellitus" [MeSH Terms] OR ("diabetes" [All
Fields] AND "mellitus" [All Fields]) OR "diabetes mellitus"
[All Fields] OR "diabetes" [All Fields] OR "diabetes
insipidus" [MeSH Terms] OR ("diabetes" [All Fields] AND
"insipidus" [All Fields]) OR "diabetes insipidus" [All Fields])
AND ("brazil" [MeSH Terms] OR "brazil" [All Fields]). The
search was limited to articles published in Portuguese,
English or Spanish between 2000 and October 2011,
without any restrictions on the study design or the level
(national or regional) at which the data were collected.
We included all publications providing information on
one or more of the following end-points related to dia-
betes type 2 in Brazil: prevalence and incidence, manage-
ment (treatment, access, and inequalities), complications
(retinopathy, nephropathy, neuropathy, diabetic foot
ulcers, amputation, kidney disease, fundus changes, vas-
cular complications) and direct and indirect costs.
Articles were first screened by title and then by
abstract. Full-text of selected publications were retrieved
and examined regarding eligibility. Reference lists of
the selected articles were scrutinized in order to iden-
tify relevant references. Official documents from the
Brazilian government and the World Health Organi-
zation (WHO) were also examined. In addition, we iden-
tified unpublished work in the grey literature through
Google, the researchers’ own knowledge and consulta-
tions with diabetes experts in Brazil.
Results and discussion
We identified 2,699 articles published between 2000
and October 2011. The screening phase enabled us to
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tailed evaluation. Forty-two publications met the eligibil-
ity criteria (Table 1).
Data sources on diabetes in Brazil
The Ministry of Health has developed a comprehensive
surveillance system for NCDs and their risk factors [17].
For diabetes, data is available on morbidity (Hospital
Information Systems, Ambulatory Information System,
and Hypertension and Diabetes Registration and Follow-
up system), mortality (single cause or multiple causes)
and risk factors (routine data collection through surveil-
lance systems and surveys) [17].
The Hospital Information System (SIH-SUS) [17] is a
national system that aggregates patient level data on
hospital admissions, primary cause of admission, diagno-
sis, procedures, length of stay and reimbursement by
SUS. The system is set up to allow download and tabula-
tion of data at the municipal level. The scope of the sys-
tem is limited to SUS admissions and does not include
any information on admissions covered by private health
insurance or paid out-of-pocket. It is estimated that SIH-
SUS covers 60% to 70% of all hospital admissions in the
country, although with large variations across regions.
As part of the Ambulatory Information System (SIA-
SUS) [17] information is collected on so-called ‘highly
complex procedures’. This includes data on treatment
and exams in the areas of nephrology, cardiology, oncol-
ogy, orthopaedics, ophthalmology among others. From
this dataset it is possible to extract relevant information
on screening and management of diabetes and its com-
plications. For example, Georg et al. [59] performed an
economic analysis using secondary data from the SIA-
SUS (fasting plasma glucose measurement in order to
confirm diagnosis of diabetes), aiming to estimate the
cost-effectiveness of the screening programme for dia-
betes mellitus in Brazil.
The registration and follow-up system for hyperten-
sion and diabetes (HiperDia) [15] is a computerised
system restricted to health system units that register
prospective information on patients with hypertensionTable 1 Literature review
Area of diabetes
management
Number of
publications
retrieved
References
Prevalence, incidence and
mortality
15 [17-30]
Prevalence and costs of
complications
13 [15,17,21,31-40]
Management: treatment,
access and inequality
6 [41-46]
Outcomes 6 [47-52]
Direct and indirect costs 7 [23,53-58]and diabetes who are registered with a health unit or
primary health care team. Aggregate data and reports
are accessible online. This database includes information
on the number of patients with hypertension, types 1
and 2 diabetes, the number of patients who are obese,
smokers, physically inactive, as well as those diagnosed
with other chronic complications (e.g. dyslipidaemia)
[17]. It is estimated that 31.1% of patients with known
diabetes in Brazil are registered in the HiperDia System
[15]. However, there are concerns about the quality of
the data. A recent study identified inaccuracies and con-
tradictions in the information reported, indicating the
need for additional training and more specific clinical
and laboratory criteria to enhance identification of dia-
betes and hypertension-related complications [60].
The mortality information system (SIM) collects infor-
mation on deaths nationwide [61]. The system includes
reliable information on age, gender, place of residence
and cause of death classified according to the Inter-
national Classification of Diseases version 10 (ICD-10).
Problems of misclassification regarding cause of death
and coverage gaps are known in the north and northeast
of the country [62]. However, even in these regions,
major improvements have been documented in the re-
cent years [17].
VIGITEL is a surveillance system of risk and protect-
ive factors for chronic NCDs through telephone inter-
views [63]. It was launched in 2006 in all capitals of the
26 Brazilian states including the Federal District and has
been conducted since then on an annual basis. Each an-
nual survey includes around 2,000 participants from
each of the 27 capital cities with results weighted for the
availability of land lines in each region.
The National Household Sample Survey (PNAD) pro-
vides periodic surveillance data on NCDs nationwide.
Reports summarising data by region, by state, and by
rural/urban area are accessible online [64]. The three
surveys conducted to date provided information on ac-
cess to and utilisation of health services in 1998, 2003
and 2008. In addition, the 2008 survey also included
information on morbidities caused by chronic diseases,
including diabetes [65].
The family budget survey (POF) [66] is a household sur-
vey measuring consumption, expenses and income of
Brazilian families. Previous survey rounds were conducted
in 1974/1975, 1987/1988, 1995/1996, 2002/2003 and
2008/2009. The survey provides information on the cost
of treating diabetes, which allows for assessment of the
disease’s impact on households budgets, for example [46].
The national demographic and health survey (PNDS)
is part of the MEASURE DHS project [67], focusing on
women of child-bearing age and children under five in
Brazil. The PNDS was first conducted in 1986 and
subsequently in 1996 and 2006; however, data on the
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medicines were only collected in 2006 [68].
The Brazilian longitudinal study of adult health
(ELSA-Brasil) [69,70] is a multicentre cohort study funded
by the Ministry of Health to investigate diabetes and car-
diovascular disease (CVD) incidence, risk factors and
complications. The baseline evaluation was completed in
December 2010 and included 15,105 civil servants aged
35–74 years from six public universities in the northeast,
south and southeast regions of Brazil. Annual telephone
interviews are conducted to monitor the health status of
each participant enrolled in the baseline [69].Prevalence of diabetes and diabetes-related mortality
In 2012, the International Diabetes Federation (IDF) es-
timated the prevalence of diabetes in Brazil to be 10.3%
[71]. In the next paragraphs we summarise evidence on
the prevalence of diabetes and diabetes-related mortality
since 1986 across different regions in Brazil.
From 1986 to 1988, a multicentre study on diabetes
was conducted in nine Brazilian state capitals, including
a sample of 21,847 subjects first screened by fasting ca-
pillary glucose (FCG) [21]. The prevalence of diabetes
was estimated at 7.6% among subjects aged 30–69 years.
A concerning finding was that 46.5% of the cases were
undiagnosed. In addition, out of those who were aware
of their diabetes condition, 22.3% were not receiving any
type of diabetes treatment. The prevalence of diabetes
did not vary according to sex, ethnicity and level of edu-
cation, but increased markedly with age, from 2.7%Table 2 Studies of the prevalence of diabetes in Brazil1
First author (year) Site Year of study Sample size
Goldenberg (1996) [25] São Paulo, SP 1986-1988 2,007
Malarbi (1992) [49]
Nine Brazilian
1988 21,847
state capitals
Torquato (2003) [30] Ribeirão Preto, SP 1996-1997 1,473
Passos (2005) [27] Bambuí, MG 1997
816 adults an
1,494 elderly
Dias da Costa (2006) [24] Pelotas, RS 2000 1,968
Souza (2003) [29]
Campos dos
Goytacazes, RJ
2001 1,039
Mendes (2011) [26] São Paulo, SP 2003 872
Schmidt (2009) [28]
27 Brazilian
2006 54,369
state capitals
Bosi (2009) [23] São Carlos, SP 2007-2008 1,116
1Data from publications of the Ministry of Health and other institutions were not in
2OGTT: oral glucose tolerance test (old diagnostic criteria for fasting glucose).
3FPG: fasting plasma glucose.among those aged 30–39 years to 17.4% among those
aged 60–69 years [21].
Since then, several other studies have been conducted
with different scopes and methodologies, as summarised
in Table 2. Most of the studies presented are based on
self-reported diabetes.
Self-reported prevalence of diabetes has been studied
on an annual basis in all state capitals since 2006. As
shown in Figure 1, within only four years, self-reported
prevalence increased from 5.3% in 2006 to 6.3% in 2010.
It is not clear whether this increase is due to increased
prevalence, increased diagnosis or both.
As shown in Figure 2, women were more likely than
men to report having diabetes, which may reflect their
higher utilisation of medical care and therefore increased
likelihood of being diagnosed [63], supporting the argu-
ment of increased detection. However, it seems likely
that higher incidence of diabetes must also have played a
role in increasing the reported prevalence of diabetes,
particularly given the parallel increase in the prevalence
of obesity epidemics in Brazil [72].
Franco et al. [73] analysed diabetes-relates deaths in
São Paulo, including data from 1975 to 1992. Diabetes
was mentioned on the certificate of 13,786 deaths
(6.8%), and referred as the underlying cause of 2.6% of
all deaths. Diabetes was also reported as an associated
cause of deaths whose underlying cause was cardiovas-
cular and respiratory diseases, as well as neoplasia.
Cesse et al. [18] analysed time trends in diabetes-
related mortality and found that mortality increased in
most state capitals between 1950 to 2000, while theAge group Diabetes prevalence Criteria
30-69 years 4.7% Self-report
30-69 years 7.6%
OGTT2 and
self-report
30-69 years 12.1%
OGTT and
self-report
d Adults (18-59 years);
elderly (60+ years).
Elderly 14.6% FPG3 and
self-reportAdults 2.3%
20-69 years 5.6%. Self-report
>18 years
6.0%
FPG
(age-adjusted prevalence)
60+ years 17.9% Self-report
aged ≥18 years 5.3% Self-report
30-79 years
5% and 13.5% OGTT and fasting
capillary glycaemia(age-adjusted prevalence)
cluded in the table.
5.3 5.3
5.2
5.8
6.3
4
4.5
5
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7
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Figure 1 Prevalence of diabetes in Brazil between 2006 and
2010, according to the VIGITEL.
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Teresina-PI (55.1%), Recife-PE (27%) and Natal (21.7%).
This is consistent with the rapid demographic transition
seen in Brazil during this period [2] as well as with
the increased prevalence of diabetes. Mortality figures
underestimate the burden of diabetes, since the under-
lying cause of death (including diabetes) is not accoun-
ted in the final cause of death estimates. Coeli et al. [19]
examined 2,974 death certificates of older adults and
found that 291 subjects had diabetes as one of the re-
ported causes of death. However, only 150 subjects had
diabetes as the underlying cause of death.
Diabetes was estimated to be responsible for 278,778
years of potential life lost for every 100,000 people [17].
Disability adjusted life years (DALYs) due to diabetes
and its complications were estimated in the five regions0
5
10
15
20
25
18-24 25-34 35-44 45-54 55-64 65 or more
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s 
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Figure 2 Prevalence of diabetes in Brazil by sex and age
groups. VIGITEL, 2010.of Brazil [20,22] – results showed that diabetes was re-
sponsible for 5.1% (6.0% among women and 4.4% among
men) of the total DALYs in the country.
Diabetes complications
It is estimated that about 7% of patients with diabetes
had one or more of the following complications: diabetic
foot ulcers, amputation, kidney disease, fundus changes
[15]. Detailed information regarding studies on diabetes
complication in Brazil is shown in Table 3.
A study of 1,374 patients with diabetes seen in family
health units in Recife, Pernambuco state found a 9%
prevalence of diabetic foot [40]. Routine screening for
diabetic foot is limited by the lack of trained podiatrists
and appropriate supplies. With the exception of a few
treatment centres, most health services, particularly
primary health care, do not perform foot screening for
patients at high risk of developing complications [36].
According to the Brazilian Ministry of Health, diabetic
retinopathy (DR) is the leading cause of irreversible
blindness in Brazil. Asymptomatic in its early stages, ret-
inopathy evolves over time, affecting the majority of pa-
tients who have lived with diabetes for more than 20
years [21]. It is estimated that 20 to 40% of patients with
type 2 diabetes are affected by DR, based on studies
among specific groups and restricted areas [38,74-76].
The narrow focus of these studies and limited geograph-
ical coverage make it difficult to estimate the national
prevalence.
Diabetic nephropathy (DN) is another common and
devastating complication in patients with diabetes, with
a slightly lower frequency than retinopathy [31]. Similar
to other countries, chronic kidney disease has been an
important public health problem in Brazil. It is estimated
that at least one third of Brazilians with type 2 diabetes
are affected by DN [34,35].
Data available from the High Complexity Procedures
Authorisation Subsystem on Renal Replacement Therapy
(APAC/TRS) [17] shows that between 2000 and 2006,
148,284 patients began dialysis treatments (predomin-
antly haemodialysis) in Brazil. The incidence of terminal
disease patients starting replacement therapy was esti-
mated to be 119.8/1,000,000 inhabitants/year, varying
from 143.6/1,000,000/year in the south of Brazil to 66.3/
1,000,000/year in the north of the country [17,33].
Hypertension was reported as the leading cause of renal
disease (22%), followed by diabetes mellitus (13.8%) and
glomerulonephritis (7.2%) [17]. Undetermined causes
were cited frequently (44.8%), indicating the need to im-
prove the quality of the information recorded. Incidence
of terminal disease patients starting dialysis increased in
patients over 65 years, most likely related to population
aging and greater use of renal replacement therapy
among the elderly [33].
Table 3 Studies on diabetes complications in Brazil
First
author (year) City, State
N of patients
with type 2 diabetes
Data collection
Complication Prevalence
Place Source of data
Bruno (2000)
[32]
Porto
Alegre, Rio
Grande do
Sul
93 Dialysis centres
Standardized questionnaire, clinical interview,
and review of medical records
Diabetic
nephropathy
58.0%
Diabetic
retinopathy
85.0%
Peripheral
vascular
disease
73.0%
Scheffel
(2004) [37]
Rio Grande
do Sul
927 Health care units
Clinical examination
and laboratory tests
Coronary
artery disease
36.0%
Diabetic
retinopathy
48.0%
Ischemic
heart disease
36.0%
Peripheral
vascular
disease
33.0%
Tres (2007)
[39]
Passo
Fundo, Rio
Grande do
Sul
340
Outpatient
Diabetes Clinic of
Hospital São
Vicente de Paulo
Questionnaire and
neurological tests
Diabetic
nephropathy
29.5%
Diabetic
neuropathy.
22.0%
Diabetic
retinopathy
28.8%
Vieira-Santos
(2008) [40]
Recife,
Pernambuco
1,374
Primary health
care units
Medical records Diabetic foot 9.0%
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centres located in the metropolitan area of Porto Alegre
between July 1995 and October 1996 followed 111 pa-
tients with type 2 diabetes for an average period of 3.6
years. The prevalence of DN was 58% and it was the
leading cause of renal disease in 61% of all patients in
the follow-up period (63%) [32].
Ischaemic heart disease and hypertension are the most
frequent cardiovascular diseases in patients with dia-
betes. In women with diabetes, the protective effects ob-
served for cardiovascular disease in general disappears
[31]. In 2004, a cross-sectional study using a sample of
927 patients with type 2 diabetes treated at three medical
centres in Rio Grande do Sul observed a prevalence of
coronary artery disease, peripheral vascular disease and
hypertension of 36%, 33%, and 73% respectively [37].
Regarding neuropathy, it is estimated that the most
common form of the disease is distal symmetrical sen-
sory polyneuropathy [15]. In 2007, a cross-sectional
study with 340 patients with type 2 diabetes in Passo
Fundo (southern Brazil) found a prevalence of 22% of
diabetic peripheral neuropathy [39].
Despite the existence of multiple data sources, evi-
dence on the prevalence and incidence of diabetes and
its complications at national and regional level is very
scarce and originates mainly from surveys. Prevalence
data mainly originates from a number of studies that relyon self-reported data, and no study on the incidence of
diabetes was found. It seems that there is a missed
opportunity to leverage the data available through some
of the national databases such as SUS and HiperDia,
among others.
Management of diabetes in Brazil: treatment, access,
inequality
Evaluation of the health care delivered by SUS is still
done infrequently, particularly with regard to chronic
diseases. A study carried out by Assunção et al. [41] in
1998/1999 evaluated the structure, process, and out-
comes of diabetes treatment in primary health care in
Pelotas, in Southern Brazil. Approximately 85% of the
physicians in the study reported prescribing a diet plan
during their first consultation and 72% prescribed phys-
ical activity. In terms of laboratory monitoring of the pa-
tients, all physicians requested fasting blood glucose,
while only 60% requested glycosylated haemoglobin.
In 2006, the Ministry of Health published primary
health care guidelines [31] for the management of
diabetes at primary care level. The guidelines provide
recommendations on diabetes screening and prevention,
diagnosis, initial evaluation and basic treatment. Screen-
ing is recommended for asymptomatic individuals at
higher risk of diabetes according to the following
indicators: age >45 years, BMI > 25 Kg/m2, waist
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women, family history of diabetes, hypertension (>140/
90 mmHg), HDL cholesterol <35 mg/dl and/or triglycer-
ides >150 mg/dl. Recommendations on lifestyle changes,
pharmacological treatment, prevention and management
of acute and chronic outcomes of diabetes are also pro-
vided. Similar guidelines are available for hypertension
and prevention of CVD at the primary care level.
Some studies using regional samples investigated avail-
ability, affordability and access to medicines used for the
treatment of diabetes. Pinto et al. [45] analysed medicine
prices and availability using WHO/HAI methodology.
The study was performed in 2007 in 30 cities in Brazil
and found that metformin 500 mg and glibenclamide
5 mg were available in 23% and 93% of public sector
facilities respectively.
In contrast, another study [42] carried out in six cities
in the south of Brazil found total availability of metfor-
min 500 mg to be 100% in the public sector. In terms of
affordability, the study found that both metformin and
glibenclamide could cost up to two working days of
salary for non-skilled workers to purchase a monthly
course treatment. A cross-sectional study [43] evaluating
41 municipalities in South and Northeast Brazil reported
that 78.6% of patients with diabetes had access to dia-
betes medicines. Another study using the same popula-
tion [44] looked at access to diabetes medicine among
the elderly and found that 95.8% had access to medi-
cines, with the majority of medicines provided by SUS
(76.7%).
A National Survey on Medicine Access and Utilization
(PNAUM) started in 2013 and data collection is ongoing
[77]. The aim of this survey is to evaluate the national
pharmaceutical policy and whether the policy is achiev-
ing its main objective of ensuring high levels of access to
medicine for the entire population. It is the first national
study exclusively designed to evaluate the result of the
current pharmaceutical policy.Table 4 Indicators of diabetes outcomes available in Brazil
Indicator
Percent of persons with diabetes mellitus with a HbA1c tested in last 12 mo
Percent of persons tested, who have HbA1c value >7.5%
Percent of the persons with diabetes mellitus with microalbuminuria tested i
Percent of those tested with microalbuminuria
Percent of the persons with diabetes mellitus with blood pressure measurem
Percent of the persons with diabetes mellitus who are smoking
Percent of persons with diabetes mellitus with BMI≥ 25 kg/m2, BMI≥ 30 kg/
Percent of persons with diabetes mellitus with fundus inspection in the last
Percent of those tests, with proliferate retinopathy in the last 12 months
Annual incidence of amputations above the ankle in patients diabetes mellit
Annual incidence of myocardial infarction in patients with diabetes mellitus/The impact of diabetes on family expenses was investi-
gated in a study using data from POF 2002-2003 [46].
This study showed that 1.7% of the population pur-
chased at least one medicine for diabetes. The annual
average spending for those who acquired one or more
medicines for diabetes care amounted to USD $102.81.
Data from 2004 showed that glycaeted haemoglobin
(HbA1c) control (<7.0%) was attained only by 40% of pa-
tients with diabetes [51].
Diabetes outcomes indicators
Table 4 identifies indicators on diabetes outcomes avail-
able in Brazil. The main sources of data are information
systems from the Ministry of Health. Minimal baseline
information on each indicator is available.
Data from 2004 showed that glycaeted haemoglobin
(HbA1c) control (<7.0%) was attained only by 40% of pa-
tients with diabetes [51]. Further, it is estimated that
about 7% of individuals with diabetes had one or more
of the following complications: diabetic foot ulcers, am-
putation, kidney disease, fundus changes [15].
A multicentre study conducted in five countries, inclu-
ding Brazil, identified that no country has reached
the standard for HbA1c or blood pressure set by the
American Diabetes Association Diabetes Physician Recog-
nition Programme [52]. In 2007, a cross-sectional multi-
centre study conducted in nine Latin American countries
(Argentina, Brazil, Chile, Costa Rica, Ecuador, Guatemala,
Mexico, Peru, and Venezuela), including a sample of 878
Brazilians aged 18 to 75 years with type 2 diabetes, showed
that about 40% of participants had controlled glycosylated
haemoglobin (HbA1c <7.0%) [51].
Very few studies have been conducted to evaluate the
quality of treatment and to measure differences between
SUS and privately insured patients. A retrospective co-
hort study was carried out in Southern Brazil involving
80 patients treated in a SUS outpatient clinic and 277
patients treated at a private clinic. Patients receivingSource
nths Surveys
Surveys
n last 12 months Surveys
Surveys
ents in last 12 months SisHiperDia
SisHiperDia Vigitel
m2 SisHiperDia Vigitel
12 months SisHiperDia
SisHiperDia
us/100,000 general population Surveys
100,000 general population SisHiperDia
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control, although only the values of HbA1c and total
cholesterol were statistically different between the two
groups [50]. However, due to the small sample size and
the regional coverage of this study, these findings are
not representative of the whole Brazilian population.
Costs related to diabetes and its complications
In 2008, the World Bank estimated that countries such
as Brazil, China, India and Russia lose more than 20
million productive life-years due to NCDs annually [78].
A study across several Latin and Central American
and Caribbean countries [79] estimated that in 2000, the
total annual costs (direct and indirect) of diabetes in
Brazil were USD $22.6 billion. Direct costs included
medications, hospitalisations, consultations, and treat-
ment for complications and totalled to US $3.952 billion.
This represented a direct cost per capita of US $872.
Indirect costs included loss of income by permanent and
temporary incapacity as well as premature death, and
amounted to USD $18.6 billion. Across all twenty-five
Latin American and Caribbean countries included in the
analysis, Brazil had the highest estimated indirect and
direct costs for diabetes among the countries studied.
Bahia et al. [54] estimated direct and indirect costs of
type 2 diabetes using data collected during 1,000 inter-
views carried out in 2007 in eight Brazilian cities. The
total annual cost per patient was USD $2,108, of which
63.3% were direct costs (USD $1,335) and 36.7% indirect
costs (USD $773).
McLellan et al. [55] estimated the cost of clinical treat-
ment and hospital expenses to be around USD $710
per patient/year in 2001. This estimate was based on
93 people with diabetes in the city of Piracicaba - São
Paulo - hospitalised between March and June 2001, and
therefore unlikely to be nationally representative.
Rosa et al. [57] calculated expenses for hospitalisation
due to diabetes using national data for the period of
1999–2001. It was estimated that the average cost per
hospitalisation resulting in patient death is USD $275.27;
in comparison to USD $143.45 when hospitalisation did
not result in death [57]. Hospitalisation rates for patients
with diabetes have been stable in the past few years, ran-
ging from 65 to 75 per 100,000 inhabitants per year.
Abegunde et al. [53] predicted that losses due to re-
duced productivity at work and the decreased family in-
come as a result of diabetes, heart disease and stroke
would lead to an economic loss amounting to USD
$4.18 billion from 2006 to 2015 in low and middle-
income countries.
A study using DATASUS data estimated the direct
cost of hospitalisation due to diabetes to be USD
$362,945,412 in 2000 [58]. Another study [56] simulated
a hypothetical cohort including 6.48 million participantswith type 2 diabetes, based on estimates from the
Brazilian Ministry of Health, hospital budgets and ex-
pense records in 2008. The estimated annual total cost of
hospitalisation was USD $264 million (converted using
2008 rate of exchange US$1 = R$1.64), while the costs re-
lated to amputation totalled USD $128 million [56].
Health policy related to diabetes
In 1987, a multicentre study on the prevalence of dia-
betes and impaired glucose tolerance was conducted in
nine Brazilian capitals among adults aged 30–69. This
study indicated that half of the individuals with diabetes
were not aware of their health condition [21].
In an attempt to address the high level of unawareness
about diabetes, the first national diabetes screening cam-
paign was launched in 2001 and implemented by public
health services in Brazil. The target population was SUS
users aged 40 years or older. The estimated national
coverage of the campaign among the SUS target popula-
tion was 73% [80]. Twenty million people were screened
using capillary glycaemia tests and approximately 3.3
million (16.5%) suspected cases of diabetes were identi-
fied [81].
The Primary Health Care Department within the
Health Care Secretariat develops measures to control
and assess services from the primary health care and
provides technical support to states, cities, and the
Federal District. The Department organises basic health
services including the Family Health Programme (PSF),
oral health, hypertension and diabetes (HiperDia), food
and nutrition, management and strategies, evaluation
and follow-up activities [81].
According to the guidelines from HiperDia, risk pre-
vention and care of patients with diabetes should take
place at primary health care level [17]. The Family
Health Strategy [5] was introduced in 1994, aiming to
reorganise primary health care through the implementa-
tion of multi-disciplinary professional teams. These
teams are responsible for the follow-up of a defined
number of families located in a limited geographical
area. The teams work on health promotion actions,
prevention, recuperation, rehabilitation, and the main-
tenance of community health. The strategy aims to
rationalise the use of all levels of assistance (primary,
secondary and tertiary) and it has produced positive re-
sults for the main health indicators in the populations
benefitting from the family health teams.
SUS provides essential medicines for diabetes control
without additional costs for the system’s users. The free
distribution of medicines in Brazil began in 1971,
focusing on the poor population [82]. The Brazilian
programme Popular Pharmacy was created in 2004 as a
partnership between the federal government and states/
municipalities aiming at increasing access to low-cost
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In 2006, this strategy was expanded to include private
pharmacies and drug stores, named “Aqui Tem Farmá-
cia Popular” (Popular Pharmacy is Available Here) [82].
As part of this programme, the Ministry of Health began
subsidising 90% of the reference price of 24 medicines
for the treatment of hypertension, diabetes, asthma,
rhinitis, Parkinson disease, osteoporosis and glaucoma.
This programme covers more than 2,500 municipalities
and is available to 1.3 million Brazilians in need of
medication (patients for whom drugs were prescribed),
including 300,000 patients with diabetes [17].
In September 2006, a law was enacted to ensure the
free distribution of diabetic medicines and the necessary
equipment to monitor capillary glycaemia for all SUS
insurees. In 2007, it was established that free medicines
would be available to patients with diabetes, although
the free distribution was restricted to patients whose
treatment was provided by the SUS in primary health
care units. In March 2011, the Brazilian government
launched a programme called “Saúde Não Tem Preço”
(Health has no price), to expand access to medicines for
diabetes and hypertension. In this programme, the phar-
macies and drugstores linked to the popular pharmacy
network started to offer free medicines for the treatment
of hypertension and diabetes (glibenclamide, metformin
and insulin) in more than 17,500 registered private phar-
macies [17]. A month after its launch, more than 3.7
million treatments were distributed, representing an in-
crease of 70% in the distribution of medicines for hyper-
tension and diabetes [17].
Brazil has participated in health promotion campaigns
related to diabetes such as World Diabetes Day. The
main strategy adopted by the Government to prevent
chronic diseases is to control risk factors. Preventive
efforts include anti-tobacco programmes, food and health
nutrition policies (industry self-regulation code on adver-
tising of food and beverages directed at children, regula-
tion requiring the inclusion of warnings in all forms of
advertising for products containing high levels of fat,
sugars or salt), school health promotion, and actions to
ensure essential medicines are provided in the public sec-
tor for hypertension and diabetes [17,83].
The Health Gym Programme was created in order to
promote physical activity and provide free-of-charge spaces
and support for living a healthy lifestyle [17]. According to
the strategic action plan for coping with chronic diseases
in Brazil from 2011 to 2022, the programme’s goal is to
reach 4,000 municipalities by 2015 [84].
Actions for the future
Recently the Brazilian Ministry of Health launched the
National Strategy for the Prevention and Control of
NCDs for the period 2011–2022 [17]. The plan aims toprepare Brazil to confront and prevent the major
chronic NCDs in the next ten years.
The Brazilian National Policy on Health Promotion
[85] has prioritised drafting regulatory measures aimed
at promoting healthy eating to reduce the prevalence of
NCDs, with special emphasis on the regulation of food
marketing and advertising, encouraging physical activity
through gym classes at community levels, and imple-
menting health promotion strategies in schools.
The expansion of pharmaceutical care and the free
distribution of more than 15 medications for hyperten-
sion and diabetes play an important role in the Brazilian
Government’s effort to tackle diabetes. In September
2011, Brazilian President Dilma Rousseff attended a gen-
eral assembly summit at the UN headquarters in New
York, contributing to global efforts in confronting the
problem of NCDs [6]. The President reported that one
of the first measures of her government was to increase
access to medicines for poor patients with hypertension
and diabetes. According to the President, 5.4 million
Brazilians have taken advantage of the programme.
Conclusions
According to the latest IDF estimates, the prevalence of dia-
betes in Brazil was 10.3% in 2012. However, this national
level estimate hides important intra-country variation.
In the last few years, the Brazilian Ministry of Health
has invested considerably in surveillance systems on
NCDs. As a result, our review identified a number of
data sources relevant to the study of diabetes covering
morbidity (SIH-SUS HiperDia), mortality (SIM), risk fac-
tors (VIGITEL, ELSA), access and utilisation of health
care services (PNAD, POF). However, it seems that the
country is still not capitalising on available national data
to produce the necessary evidence to identify gaps and
formulate appropriate policy responses.
Data on diabetes costs are patchy and out-of-date. A
multicountry study estimated that the total annual costs
(direct and indirect) of diabetes in the country were
USD $22.6 billion in 2000, representing a direct cost per
capita of US $872. A more recent study estimated the
direct and indirect costs of diabetes to be USD $ 2,108
per capita in 2007. There is some evidence on hospital-
isation costs but no evidence on the cost of various
types of complications.
A number of policies and programmes have been in-
troduced by the Brazilian government in an attempt to
improve access to diabetes care and reduce the preva-
lence of the disease. These include a national diabetes
screening campaign in 2001, the Brazilian Popular
Pharmacy programme introduced in 2004 and prevent-
ive efforts addressing risk factors (regulation of the food
industry, promotion of physical activity through the
health gym programme and anti-tobacco programmes).
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Ministry of Health has adopted several strategies to
reduce the costs of the disease in the Brazilian popula-
tion, highlighting the interventions to be taken at the
primary health care level. Specific programmes were im-
plemented aimed at managing diabetes. However, some of
the gaps include weak evaluation of the SUS in providing
good quality care for patients with diabetes and lack of
data on inequalities in access to medicines and health care
services including annual testing for complications.
In conclusion, Brazil has the capacity to address and
respond to NCDs due to the availability of federal, state
and local integrated health programmes currently in op-
eration. There is funding available for NCDs treatment,
control and prevention, as well as health promotion, sur-
veillance, monitoring and evaluation activities. However,
these resources need to be used in the right way to be
effective.
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